The ‘slam dunk’ that wasn’t: Promising cholesterol drug fails to prevent heart attacks or stroke
A large-scale clinical trial involving 8,322 participants revealed that the experimental drug pelacarsen failed to reduce rates of heart attacks, strokes, or cardiovascular deaths despite significantly lowering levels of lipoprotein(a) cholesterol. The study, known as the Horizon trial, was led by Dr. Steven Nissen of the Cleveland Clinic and presented at the American Heart Association meeting. Although the drug reduced lipoprotein(a) levels by 78% compared to a 13% reduction in the placebo group, these biochemical improvements did not translate into better patient outcomes. Researchers expressed surprise at the null result, noting that previous assumptions suggested lowering this specific genetic marker would protect against cardiovascular events. The findings challenge current preventive cardiology strategies and highlight the complexity of treating genetically determined high cholesterol levels.
Novartis announced Saturday that its experimental cholesterol drug, pelacarsen, failed to prevent heart attacks, strokes, or cardiovascular death in a large clinical trial. The results, presented at the American Heart Association scientific sessions and published in the New England Journal of Medicine, showed no measurable benefit for patients with high levels of lipoprotein(a), or Lp(a). This outcome shocked researchers who had viewed the therapy as a potential breakthrough in preventive cardiology. The trial, named Horizon, involved 8,322 individuals who had previously suffered a heart attack, stroke, or other cardiac issue within ten years of enrollment. Despite the drug reducing Lp(a) levels by 78 percent compared to a 13 percent reduction in the placebo group, these biochemical improvements did not translate into fewer major cardiovascular events. Lp(a) is a genetically determined form of cholesterol that contributes to arterial plaque buildup and blood clot formation. Unlike standard bad cholesterol, Lp(a) levels are fixed at birth and cannot be altered by diet or exercise. Approximately one in five Americans carries elevated levels of this particle, though many remain unaware of their risk. Because the condition is hereditary, medical professionals had long sought pharmacological interventions to mitigate the associated dangers. The Horizon trial was designed to test whether suppressing Lp(a) would protect against future cardiac incidents in high-risk populations. Dr. Steven Nissen, chief academic officer at the Cleveland Clinic’s Heart, Vascular & Thoracic Institute, led the study. He expressed extreme surprise at the neutral results, noting that the medical community broadly believed substantial reductions in Lp(a) would lower the risk of major events. Nissen stated there was no evidence that greater reduction correlated with better patient outcomes. Dr. Amanda Doran, an assistant professor of medicine at Vanderbilt University Medical Center, described the expectation as a slam dunk. Vanderbilt served as one of nearly 800 sites participating in the trial. Doran noted that the team felt deeply invested in the project, making the failure particularly painful. Other cardiologists offered explanations for the lack of efficacy. Dr. Karol Watson, co-director of the UCLA Program in Preventive Cardiology, suggested the intervention may have occurred too late in life. The average participant age was 60, and the follow-up period lasted approximately five years. Since Lp(a) is present from conception, Watson argued that intervening only in later adulthood might be insufficient to reverse accumulated damage. Additionally, participants received aggressive treatments for other risk factors, including medications to lower LDL cholesterol and control blood pressure. Many likely took aspirin due to prior cardiac history, which could have mitigated the clotting risks associated with Lp(a). Watson questioned how much residual risk remained after such comprehensive management. The findings complicate recent shifts in clinical guidelines. Earlier this year, the American College of Cardiology and the American Heart Association recommended that every adult undergo a one-time blood test to measure Lp(a) levels. This recommendation reflected confidence in the particle as a critical marker of heart health. The Horizon results challenge the assumption that lowering this specific marker alone yields protective benefits. The study adds to a series of setbacks for drugs targeting specific cardiovascular pathways. Similar disappointments emerged regarding inflammation-based therapies. A separate study by Novo Nordisk, known as ZEUS, demonstrated that the monoclonal antibody ziltivekimab reduced levels of the inflammatory cytokine interleukin-6 without preventing heart attacks, strokes, or deaths. Following those initial disclosures, Novo halted two additional trials of the drug, HERMES and ATHENA, after a data monitoring committee deemed them unlikely to succeed. These concurrent failures highlight the difficulty in translating biological mechanisms into clinical protection. Researchers continue to debate the role of Lp(a) in overall cardiovascular risk assessment. While the drug successfully targeted the molecule, the absence of clinical benefit suggests that other factors may dominate the disease process in older adults. The medical community now faces the task of determining whether Lp(a) screening retains value for guiding treatment decisions beyond simple measurement. The Horizon trial results stand as a definitive negative finding for pelacarsen, ending hopes for this specific approach to managing genetic cholesterol risks. Future strategies may need to focus on earlier intervention or different biological targets to address the persistent threat posed by inherited lipid abnormalities.
Go to the primary sources (3)
The official sources this coverage is built on. Read them directly to bypass framing.
A large-scale clinical trial involving 8,322 participants revealed that the experimental drug pelacarsen failed to reduce rates of heart attacks, strokes, or cardiovascular deaths despite significantly lowering levels of lipoprotein(a) cholesterol. The study, known as the Horizon trial, was led by Dr. Steven Nissen of the Cleveland Clinic and presented at the American Heart Association meeting. Although the drug reduced lipoprotein(a) levels by 78% compared to a 13% reduction in the placebo group, these biochemical improvements did not translate into better patient outcomes. Researchers expressed surprise at the null result, noting that previous assumptions suggested lowering this specific genetic marker would protect against cardiovascular events. The findings challenge current preventive cardiology strategies and highlight the complexity of treating genetically determined high cholesterol levels.
Bias read (Center): The article reports on scientific trial results using neutral language and balanced expert quotes regarding medical efficacy rather than political ideology.
Why factuality (95): Accurately reports the core facts of the HORIZON trial: the drug pelacarsen significantly reduced Lp(a) levels (by 78%) but failed to show statistically significant reductions in major adverse cardiovascular events (heart attack, stroke, death, etc.). It correctly identifies the trial name, the spon
Why objectivity (90): Maintains a professional, journalistic tone. While it uses slightly dramatic phrasing like 'stunned researchers' and 'massive blow,' these are attributed to the reaction of the medical community rather than being the author's own opinion. The piece balances the disappointment of the negative result
Novartis disclosed detailed results from the Phase 3 HORIZON trial regarding its experimental drug pelacarsen, which targets lipoprotein(a) (Lp(a)), a genetic risk factor for cardiovascular disease affecting approximately one in five people. Although the drug successfully and significantly lowered Lp(a) levels in patients, the study found no statistically significant reduction in major adverse cardiovascular events, including heart attacks, strokes, urgent coronary revascularizations, or deaths over nearly five years of follow-up. These findings were presented at the American Heart Association’s scientific sessions and published concurrently in the New England Journal of Medicine. The failure of the therapy to improve clinical outcomes despite lowering the biomarker has raised broader questions about the validity of targeting Lp(a) as a strategy for preventing cardiovascular disease.
Bias read (Center): The article presents objective clinical trial data and standard medical terminology without using loaded language, partisan framing, or biased sourcing, focusing strictly on the scientific outcome.
Why factuality (90): Factually sound based on the visible text. Correctly identifies the drug, the sponsor, the trial name (HORIZON), and the outcome (reduced Lp(a) but no reduction in hard endpoints). Mentions the simultaneous publication in NEJM, which aligns with standard reporting for such major trials. The descript
Why objectivity (95): Highly objective and concise. Uses neutral language ('took a hit', 'failed to lower') to describe the negative trial results. Avoids emotional adjectives or speculative commentary. Presents the facts clearly without injecting bias or spin, making it a very balanced summary of the event.
Recent clinical trial results indicate that the experimental drug ziltivekimab, developed by Novo Nordisk, failed to reduce serious cardiovascular events despite lowering levels of the inflammatory biomarker interleukin-6. The ZEUS study demonstrated that while the monoclonal antibody successfully targeted inflammation markers, it did not lead to fewer heart attacks, strokes, or deaths compared to a placebo. Following these findings, Novo Nordisk halted two additional trials named HERMES and ATHENA because a data monitoring committee determined they were unlikely to succeed. The detailed results were presented at the American Heart Association’s scientific sessions and published in the New England Journal of Medicine. Cardiologists continue to explore anti-inflammatory treatments for cardiovascular disease despite this specific setback.
Bias read (Center): The article reports on clinical trial outcomes using neutral medical terminology and cites primary scientific publications without employing partisan language or political framing.
Why factuality (85): Focuses on a different aspect of the same AHA conference (the ZEUS trial for ziltivekimab) rather than the pelacarsen trial mentioned in Articles 0 and 1. However, since the prompt states all articles cover the 'same event' (likely referring to the broader context of recent cardiovascular drug failu
Why objectivity (90): Objective and analytical. Frames the failure of the anti-inflammatory approach neutrally, noting that cardiologists will continue to pursue the strategy despite the setback. Does not use sensationalist language. Provides a balanced view of the implications for future research directions without favo
Two recent clinical trials presented at the American Heart Association meeting failed to show benefits for drugs intended to prevent heart attacks and strokes. One trial involving Novartis’s pelacarsen demonstrated no reduction in cardiovascular events despite successfully lowering the blood marker Lp(a). A second large-scale study by Novo Nordisk testing an anti-inflammatory drug targeting the IL-6 protein also yielded negative results. These outcomes contradict earlier genetic assumptions that suggested these specific biological targets would reduce cardiovascular risk. The author uses these repeated scientific setbacks to argue that such failures should temper public enthusiasm regarding the potential of artificial intelligence and other emerging technologies to rapidly solve complex medical challenges.
Bias read (Center): The piece focuses on scientific data and technological skepticism rather than partisan politics, using neutral language to describe clinical trial outcomes without attributing blame to specific political actors or parties.
How each side covered it
The same event, grouped by the political lean of the outlets covering it.
progressive
center
conservative
★
How each side covered it
Support independent, bias-aware news and unlock the social pulse, community voting, and every other Supporter feature.